196 related articles for article (PubMed ID: 15939196)
1. Gastrointestinal stromal tumors.
von Mehren M; Watson JC
Hematol Oncol Clin North Am; 2005 Jun; 19(3):547-64, vii. PubMed ID: 15939196
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal stromal tumors (GISTs): a pathology view point.
Sornmayura P
J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
[TBL] [Abstract][Full Text] [Related]
3. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
Shiba K; Matsumoto T; Hirota S
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal stromal tumors and the evolution of targeted therapy.
Sanborn RE; Blanke CD
Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S
J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
[TBL] [Abstract][Full Text] [Related]
6. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
[TBL] [Abstract][Full Text] [Related]
7. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
8. Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment.
Sakamoto K; Sakurai S; Kanda T; Sakuma Y; Hishima T; Hironaka M; Bamba T; Keira Y; Takano Y; Niki T; Hasegawa T; Hirota S
Cancer Sci; 2010 May; 101(5):1270-8. PubMed ID: 20180814
[TBL] [Abstract][Full Text] [Related]
9. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.
Yeh CN; Chen TW; Tseng JH; Liu YY; Wang SY; Tsai CY; Chiang KC; Hwang TL; Jan YY; Chen MF
J Surg Oncol; 2010 Nov; 102(6):599-603. PubMed ID: 20976730
[TBL] [Abstract][Full Text] [Related]
10. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
11. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
Renouf DJ; Wilson L; Blanke CD
Clin Cancer Res; 2009 Jun; 15(12):3908-11. PubMed ID: 19509180
[TBL] [Abstract][Full Text] [Related]
12. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
[TBL] [Abstract][Full Text] [Related]
13. Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment.
Sleijfer S; Wiemer E; Verweij J
Nat Clin Pract Oncol; 2008 Feb; 5(2):102-11. PubMed ID: 18235442
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy.
Samelis GF; Ekmektzoglou KA; Zografos GC
Eur J Surg Oncol; 2007 Oct; 33(8):942-50. PubMed ID: 17196360
[TBL] [Abstract][Full Text] [Related]
15. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
16. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
17. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
[TBL] [Abstract][Full Text] [Related]
18. The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness.
Kosmadakis N; Visvardis EE; Kartsaklis P; Tsimara M; Chatziantoniou A; Panopoulos I; Erato P; Capsambelis P
Surg Oncol; 2005 Aug; 14(2):75-84. PubMed ID: 15993051
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesilate for the treatment of gastrointestinal stromal tumour.
Cassier PA; Dufresne A; Arifi S; El Sayadi H; Labidi I; Ray-Coquard I; Tabone S; Méeus P; Ranchère D; Sunyach MP; Decouvelaere AV; Alberti L; Blay JY
Expert Opin Pharmacother; 2008 May; 9(7):1211-22. PubMed ID: 18422477
[TBL] [Abstract][Full Text] [Related]
20. [Imatinib mesylate STI571 therapy for five patients with advanced gastrointestinal stromal tumors].
Shen KT; Hou YY; Qin XY; Song LJ; Sujie A
Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Mar; 8(2):129-31. PubMed ID: 16155822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]